TIANXIN PHARMA(SH:603235)2023-04-28 16:00Financial Performance - The company's revenue for Q1 2023 was ¥578,115,710.93, representing a decrease of 4.61% compared to the same period last year[17]. - Net profit attributable to shareholders for Q1 2023 was ¥108,598,608.80, down 39.04% year-on-year[17]. - The diluted earnings per share for Q1 2023 was ¥0.25, reflecting a decline of 44.44% compared to the previous year[17]. - Operating revenue from sales and services received cash of CNY 492,513,431.35, down from CNY 559,567,772.02 in the same period last year, indicating a decrease of about 12.0%[34]. - Total operating revenue for Q1 2023 was $578.12 million, a decrease of 4.2% compared to $606.09 million in Q1 2022[53]. - Net profit for Q1 2023 was ¥114,682,958.59, representing a decline of 35.2% compared to ¥176,767,029.08 in Q1 2022[65]. - The total profit for Q1 2023 was ¥135,338,692.30, a decrease of 34.4% from ¥206,819,949.29 in Q1 2022[64]. Costs and Expenses - The total operating costs amounted to CNY 395,953,210.32, compared to CNY 353,749,728.05 in the previous year, reflecting an increase of approximately 11.9%[30]. - Total operating costs increased to $454.33 million in Q1 2023, up from $413.55 million in Q1 2022, reflecting a rise of 9.8%[53]. - Research and development expenses for Q1 2023 were CNY 16,067,191.19, slightly up from CNY 15,559,462.59 in Q1 2022, showing an increase of about 3.3%[30]. - Research and development expenses decreased to ¥6,552,836.78 in Q1 2023 from ¥10,854,372.54 in Q1 2022, a reduction of 39.9%[64]. - The company incurred a financial expense of CNY 201,558.70, a significant decrease from CNY 4,796,682.23 in the previous year, indicating a reduction of approximately 95.8%[30]. - The company's financial expenses significantly decreased to ¥156,951.62 in Q1 2023 from ¥4,673,000.64 in Q1 2022[64]. - Tax expenses for the quarter were CNY 22,052,302.71, down from CNY 31,915,799.50 in Q1 2022, reflecting a decrease of about 30.9%[30]. - Tax expenses for Q1 2023 were ¥20,655,733.71, down from ¥30,052,920.21 in Q1 2022, reflecting a decrease of 31.2%[64]. Cash Flow and Assets - The net cash flow from operating activities increased by 37.92% to ¥181,083,879.64, mainly due to increased government subsidies and fundraising interest[7]. - The company reported a net cash inflow from operating activities of CNY 181,083,879.64, which is an increase from CNY 131,293,689.29 in the same quarter last year, representing a growth of approximately 37.9%[34]. - Net cash flow from operating activities for Q1 2023 was CNY 192,715,107.29, compared to CNY 151,613,970.09 in Q1 2022, indicating an increase of approximately 27.14%[42][43]. - Cash and cash equivalents increased to CNY 2,268,618,703.45 from CNY 2,054,246,268.02, representing a rise of about 10.43%[38][43]. - Cash and cash equivalents at the end of Q1 2023 totaled $2.38 billion, significantly up from $241.55 million at the end of Q1 2022[59]. - Total assets at the end of Q1 2023 amounted to ¥4,740,703,136.99, an increase of 1.30% from the end of the previous year[5]. - As of March 31, 2023, total assets amounted to CNY 4,739,911,936.44, an increase from CNY 4,663,579,989.81 as of December 31, 2022, reflecting a growth of approximately 1.63%[38][40]. - Total assets increased to $4.74 billion in Q1 2023, compared to $4.68 billion in Q1 2022, marking a growth of 1.3%[58]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,666[9]. - The equity attributable to shareholders at the end of Q1 2023 was ¥4,169,064,254.29, up 2.74% from the end of the previous year[5]. - Shareholders' equity rose to $4.18 billion in Q1 2023, up from $4.06 billion in Q1 2022, reflecting an increase of 2.9%[62]. Other Income and Gains - The company reported other income of CNY 7,135,011.63, down from CNY 16,620,225.03 in the previous year, indicating a decline of approximately 57.1%[30]. - Other income for Q1 2023 was ¥7,049,433.62, down from ¥16,593,090.10 in Q1 2022, a decline of 57.5%[64]. - The total amount of non-recurring gains and losses for the period was CNY 6,513,011.96, down from the previous period[21]. - The company reported interest income of ¥12,104,187.20 in Q1 2023, a significant increase from ¥258,973.53 in Q1 2022[64].